Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors

被引:32
作者
Qiao, L [1 ]
Baumann, CA [1 ]
Crysler, CS [1 ]
Ninan, NS [1 ]
Abad, MC [1 ]
Spurlino, JC [1 ]
DesJarlais, RL [1 ]
Kervinen, J [1 ]
Neeper, MP [1 ]
Bayoumy, SS [1 ]
Williams, R [1 ]
Deckman, IC [1 ]
Dasgupta, M [1 ]
Reed, RL [1 ]
Huebert, ND [1 ]
Tomczuk, BE [1 ]
Moriarty, KJ [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev, Exton, PA 19341 USA
关键词
dipeptidyl peptidase IV inhibitors; SAR; X-ray structure;
D O I
10.1016/j.bmcl.2005.09.037
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The discovery, SAR, and X-ray crystal structure of novel biarylaminoacyl-(S)-2-cyano-pyrrolidines and biarylaminoacyl-thiazolidines as potent inhibitors of dipeptidyl peptidase IV (DPP IV) are reported. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 36 条
[1]   Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors [J].
Ashton, WT ;
Dong, H ;
Sisco, RM ;
Doss, GA ;
Leiting, B ;
Patel, RA ;
Wu, JK ;
Marsilio, F ;
Thornberry, NA ;
Weber, AE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (04) :859-863
[2]   4-cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV [J].
Ashworth, DM ;
Atrash, B ;
Baker, GR ;
Baxter, AJ ;
Jenkins, PD ;
Jones, DM ;
Szelke, M .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (22) :2745-2748
[3]   2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV [J].
Ashworth, DM ;
Atrash, B ;
Baker, GR ;
Baxter, AJ ;
Jenkins, PD ;
Jones, DM ;
Szelke, M .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (10) :1163-1166
[4]   Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].
Augeri, DJ ;
Robl, JA ;
Betebenner, DA ;
Magnin, DR ;
Khanna, A ;
Robertson, JG ;
Wang, AY ;
Simpkins, LM ;
Taunk, P ;
Huang, Q ;
Han, SP ;
Abboa-Offei, B ;
Cap, M ;
Xin, L ;
Tao, L ;
Tozzo, E ;
Welzel, GE ;
Egan, DM ;
Marcinkeviciene, J ;
Chang, SY ;
Biller, SA ;
Kirby, MS ;
Parker, RA ;
Hamann, LG .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :5025-5037
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance [J].
Conarello, SL ;
Li, ZH ;
Ronan, J ;
Roy, RS ;
Zhu, L ;
Jiang, GQ ;
Liu, F ;
Woods, J ;
Zycband, E ;
Moller, DE ;
Thornberry, NA ;
Zhang, BB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (11) :6825-6830
[7]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[8]  
DEMUTH HU, 1995, DIPEPTIDYL PEPTIDASE, P1
[9]   Glucagon-like peptides [J].
Drucker, DJ .
DIABETES, 1998, 47 (02) :159-169
[10]   The crystal structure of dipeptidyl peptidase IV(CD26) reveals its functional regulation and enzymatic mechanism [J].
Engel, M ;
Hoffmann, T ;
Wagner, L ;
Wermann, M ;
Heiser, U ;
Kiefersauer, R ;
Huber, R ;
Bode, W ;
Demuth, HU ;
Brandstetter, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (09) :5063-5068